SBC Medical Group
SBC
5.34
+0.01
+0.19%
SBC Medical Group
US · SBC
#3686 by market cap
5.34
+0.01
+0.19%
Live - 5344 symbols - heartbeat 231s ago
· 2026-10-07 19:54
After-hours
5.34
0.00%
- Market cap
- 549.20M
- P/E (TTM)i
- 11.13
- P/Bi
- 2.08
- EPSi
- 0.50
- Div yieldi
- 0.00%
- 52W posi
- 94%
Reader sentiment
Are you bullish or bearish on SBC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 5.28, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year -15.48% YoY
Margins
- Gross margin
- 73.32%
- Operating margin
- 38.87%
- Net margin
- 29.37%
Key ratios & quality
- Enterprise valuei
- 432.49M
- PEG ratioi
- 0.11
- Altman Z-Scorei
- 5.28
PEG uses trailing P/E against the 3-year net income growth rate (100.61%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 174.16M | 193.54M | 205.42M | 173.61M |
| Gross profit | 114.83M | 137.30M | 156.05M | 127.28M |
| Selling & admin expenses | 93.48M | 66.23M | 70.69M | 59.80M |
| Research & development | -- | -- | -- | -- |
| Operating profit | 21.35M | 71.07M | 85.36M | 67.49M |
| Pretax profit | 23.68M | 73.58M | 73.46M | 82.07M |
| Tax | 18.12M | 35.02M | 26.77M | 31.02M |
| Net profit | 5.55M | 38.56M | 46.69M | 51.05M |
| Basic EPS | 0 | 0 | 0 | 1 |
| Diluted EPS | 0.06 | 0.39 | 0.48 | 0.50 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 47.33M | 43.36M | 43.35M | 39.57M | 43.06M | 49.19M |
| Gross profit | 37.73M | 30.01M | 30.61M | 28.93M | 30.35M | 35.98M |
| Selling & admin expenses | 12.82M | 14.39M | 13.95M | 18.63M | 12.23M | 16.19M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 24.20M | 14.55M | 15.88M | 12.85M | 17.72M | 18.96M |
| Pretax profit | 31.45M | 13.54M | 18.51M | 18.57M | 18.86M | 19.55M |
| Tax | 9.96M | 11.10M | 5.67M | 4.29M | 7.53M | 7.82M |
| Net profit | 21.49M | 2.44M | 12.83M | 14.28M | 11.33M | 11.16M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.21 | 0.02 | 0.12 | 0.14 | 0.11 | 0.10 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 112.95M | 165.91M | 184.45M | 231.22M |
| Cash & ST investments | 53.64M | 103.02M | 125.04M | 164.09M |
| Inventory | 1.35M | 3.09M | 1.49M | 2.79M |
| Total assets | 225.48M | 258.81M | 266.08M | 380.45M |
| Total current liabilities | 101.25M | 92.45M | 61.19M | 61.12M |
| Short-term debt | 8.24M | 7.41M | 4.46M | 13.65M |
| Long-term debt | 5.53M | 13.01M | 6.51M | 33.73M |
| Total liabilities | 117,632,316.00 | 114,995,022.00 | 71,060,996.00 | 117,143,240.00 |
| Total equity | 107.85M | 143.81M | 195.02M | 263.30M |
| Retained earnings | 103.48M | 142.85M | 189.46M | 240.45M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 215.10M | 241.34M | 227.20M | 231.22M | 238.78M | 259.39M |
| Cash & ST investments | 132.06M | 152.74M | 127.43M | 164.09M | 167.62M | 184.62M |
| Inventory | 1.69M | 1.71M | 1.68M | 2.79M | 2.32M | 2.98M |
| Total assets | 284.61M | 315.30M | 321.36M | 380.45M | 388.02M | 406.66M |
| Total current liabilities | 48.47M | 60.68M | 44.58M | 61.12M | 62.57M | 78.46M |
| Short-term debt | 5.78M | 7.13M | 8.38M | 13.65M | 14.63M | 17.32M |
| Long-term debt | 6.81M | 7.03M | 18.08M | 33.73M | 31.45M | 25.94M |
| Total liabilities | 58,283,354.00 | 70,646,686.00 | 73,303,884.00 | 117,143,240.00 | 117,635,399.00 | 126,743,880.00 |
| Total equity | 226.32M | 244.65M | 248.06M | 263.30M | 270.38M | 279.92M |
| Retained earnings | 210.97M | 213.42M | 226.25M | 240.45M | 251.76M | 262.45M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -47.37K | 50.67M | 20.58M | 24.67M |
| Depreciation & amortization | 5.93M | 12.25M | 3.80M | 2.68M |
| Free cash flow | -24.99M | 39.46M | 17.17M | 21.96M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 10 | 0 | -5.00M |
| Ending cash balance | 51.74M | 103.02M | 125.04M | 163.77M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.93M | -8.34M | -20.88M | 51.96M | 9.23M | 22.51M |
| Depreciation & amortization | 628.30K | 636.10K | 746.21K | 673.68K | 670.43K | 1.13M |
| Free cash flow | 1.17M | -8.85M | -21.06M | 50.70M | 8.68M | 22.04M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -2.58M | 0 | -- | -- |
| Ending cash balance | 132.06M | 152.74M | 127.43M | 163.77M | 167.31M | 184.31M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | 6.00 | 31.83 | 27.64 | 23.00 |
| ROA %i | 2.80 | 16.26 | 17.76 | 15.77 |
| ROIC %i | 4.92 | 27.47 | 25.04 | 20.09 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | 13.61 | 38.04 | 35.77 | 47.36 |
| FCF / sales %i | -- | 20.38 | 8.36 | 12.65 |
| Current ratioi | 1.12 | 1.79 | 3.01 | 3.78 |
| Quick ratioi | 0.96 | 1.69 | 2.83 | 3.55 |
| Debt / assetsi | 7.15 | 8.84 | 4.59 | 13.57 |
| LT debt / equityi | 7.50 | 10.87 | 3.97 | 15.30 |
| Interest coveragei | 754.05 | 1,625.55 | 2,596.61 | 512.05 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -0.11 |
| Net income CAGR (3Y) %i | -- | -- | -- | 100.61 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 21.80 | 13.63 | 19.13 | 23.00 | 16.93 | 19.29 |
| ROA %i | 17.34 | 10.57 | 14.02 | 15.77 | 12.13 | 13.58 |
| ROIC %i | 20.51 | 12.82 | 16.99 | 20.09 | 14.89 | 17.16 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 39.27 | 34.13 | 39.04 | 47.36 | 41.18 | 43.29 |
| FCF / sales %i | 7.76 | -- | -- | 12.65 | 17.41 | 34.46 |
| Current ratioi | 4.44 | 3.98 | 5.10 | 3.78 | 3.82 | 3.31 |
| Quick ratioi | 4.11 | 3.72 | 4.74 | 3.55 | 3.61 | 3.18 |
| Debt / assetsi | 4.95 | 4.93 | 8.76 | 13.57 | 13.38 | 11.86 |
| LT debt / equityi | 3.67 | 3.44 | 7.98 | 15.30 | 14.60 | 11.72 |
| Interest coveragei | 2,467.90 | 871.24 | 596.05 | 512.05 | 259.08 | 217.81 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- SBC Core Segment is the largest reported line at 90.83% of revenue, across 3 reported segments.
- The next-largest line, Waqoo Segment, is a distant second at 19.80% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
SBC Core Segment90.83%
Waqoo Segment19.80%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.